

Adult CIRB - Early Phase Emphasis Meeting Agenda

March 2, 2021

I Continuing Review

10150, A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer (Protocol Version Date 09/04/20)

II Continuing Review

10220, A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors (Protocol Version Date 08/25/20)

III Continuing Review

10346, Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors (Protocol Version Date 09/14/20)

IV New Study - Initial Review

CITN-17, Phase 1 Study of NT-I7 (rhIL-7-hyFc) for the Treatment of Kaposi Sarcoma in Patients With or Without Infection with HIV (Protocol Version Date 01/13/21)

V Amendment

10216, A Phase Ib Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer (Protocol Version Date 01/15/21)

VI Amendment

10349, A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas (Protocol Version Date 01/14/21)
